Paolo Guglielmi,Simone Carradori,Ilaria D&#x;Agostino et al.
Paolo Guglielmi et al.
Introduction: Monoamine oxidase (MAO) inhibitors are currently used as antidepressants (selective MAO-A inhibitors) or as co-adjuvants for neurodegenerative diseases (selective MAO-B inhibitors). The research within this ...
Butyrylcholinesterase inhibitors as potential anti-Alzheimer's agents: an updated patent review (2018-present) [0.03%]
丁卡因胆碱酯酶抑制剂作为潜在的抗阿尔茨海默病药物：2018年至今专利回顾
José G Fernández-Bolaños,Óscar López
José G Fernández-Bolaños
Introduction: Alzheimer's disease (AD) constitutes one of the most devastating diseases, with an extraordinarily high increase expected for the next few years. Despite the numerous efforts so far, there is still no cure b...
Anticancer carbonic anhydrase inhibitors: a patent and literature update 2018-2022 [0.03%]
2018-2022年抗癌碳酸酐酶抑制剂专利及文献进展更新研究报告
Sridhar Goud Nerella,Priti Singh,Mohammed Arifuddin et al.
Sridhar Goud Nerella et al.
Introduction: Cancer affects an increasing number of patients each year with an unacceptable death toll worldwide. A new therapeutic approach to combat tumors consists in targeting human carbonic anhydrase (hCA, EC 4.2.1....
Mohamed A Said,Mohamed A Abdelrahman,Mohammed A S Abourehab et al.
Mohamed A Said et al.
Introduction: The success of the CDK4/6 inhibitor Ibrance™ (Palbociclib) as an anticancer agent inspired and directed more efforts toward the discovery of selective cyclin-dependent kinase (CDKs) inhibitors. CDK2 is a me...
Carbon-11 patents (2012-2022): synthetic methodologies and novel radiotracers for PET imaging [0.03%]
碳-11专利（2012-2022）：PET成像的合成方法和新型放射性示踪剂
Sridhar Goud Nerella,Priti Singh,Sanam Tulja
Sridhar Goud Nerella
Introduction: Carbon-11 is a short-lived radionuclide with versatile applications in synthetic methodologies to develop a variety of novel PET radiotracers. Different primary and secondary carbon-11 precursors are generat...
P2X receptor antagonists and their potential as therapeutics: a patent review (2010-2021) [0.03%]
P2X受体拮抗剂及其作为药物的潜力：2010-2021年专利回顾
Chianna Dane,Leanne Stokes,William T Jorgensen
Chianna Dane
Introduction: Purinergic receptors play a critical role in neurotransmission, and modulation of complex physiological functions and thus have implications in numerous disease states. The past decade has seen substantial p...
ATP-citrate lyase (ACLY) inhibitors as therapeutic agents: a patenting perspective [0.03%]
乙酰辅酶A裂解酶(ACLY)抑制剂作为治疗剂的研究：专利视角
Carlotta Granchi
Carlotta Granchi
Introduction: ATP citrate lyase (ACLY) is a key enzyme in cellular metabolism, being the main source of acetyl-Coenzyme A, an important precursor for fatty acid, cholesterol, and isoprenoid biosynthesis, and it is also in...
Thoraya A Farghaly,Amani M R Alsaedi,Noof A Alenazi et al.
Thoraya A Farghaly et al.
Introduction: Several viral infections cause life-threatening consequences in humans, making them the most serious public health concerns. Despite the fact that several antiviral medicines are available on the market, the...
Soluble epoxide hydrolase inhibitors: an overview and patent review from the last decade [0.03%]
可溶性环氧化物水合酶抑制剂：过去十年的综述与专利分析
Malliga R Iyer,Biswajit Kundu,Casey M Wood
Malliga R Iyer
Introduction: Biological effects mediated by the CYP450 arm of arachidonate cascade implicate the enzyme-soluble epoxide hydrolase (sEH) in hydrolyzing anti-inflammatory epoxy fatty acids to pro-inflammatory diols. Hence,...
Beatrice Francucci,Diego Dal Ben,Catia Lambertucci et al.
Beatrice Francucci et al.
Introduction: A2B adenosine receptor (A2BAR) plays a crucial role in pathophysiologic conditions associated with high adenosine release, typical of airway inflammatory pathologies, gastrointestinal disorders, cancer, asth...